

736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766

Supplementary Information

SI Materials and Methods

Fig S1. PrLD predictions for Ty1.

Fig S2. Prionogenic domains are intrinsically disordered in experimental and predicted protein structures.

Fig S3. Gag_{PrLD} nucleates a Sup35-based prion reporter.

Fig S4. Gag chimeras likely disrupt Ty1 RNA functions and modestly increase cDNA recombination with plasmid-borne mini-Ty1*his3-AI*.

Fig S5. Chimeric Gag-GFP after 48 hr galactose induction.

Fig S6. Thin-section TEM of Gag-GFP strains.

Fig S7. VLP diameter of Gag-PrLD chimeras.

Supplementary Table S1. Retromobility frequencies.

Supplementary Table S2. Gag-GFP chimera fluorescent microscopy cell counts.

Supplementary Table S3. Yeast strains used in this study.

Supplementary Table S4. Plasmids used in this study.

Supplementary Table S5. Primers used in this study.

Supplementary Table S6. Gene fragments used in this study.

767

SI Materials and Methods

768

769 **Plasmids and cloning.** Plasmids, primers, and gene fragments are listed in Supplementary
770 Tables 4-6. All Ty1 nucleotide and amino acid information correspond to the Ty1H3 sequence
771 (GenBank M18706.1). All cloning was done with NEBuilder HiFi DNA Assembly Master Mix
772 (New England Biosciences cat. no. E2621). Sup35 fusion plasmids pBDG1691 (1434),
773 pSLBB027 (1134), and pSLBB028 (1258), driven by the *CUP1* promoter, were kindly provided
774 by Y. Chernoff (Chernoff lab plasmid nomenclature in parentheses). Sup35N plasmids contain
775 Sup35 amino acids 1-123, and Sup35NM contains amino acids 1-250. The Gag_{PrLD} contains
776 Gag amino acids 66-136. Gag_{PrLD} fusions to Sup35 were subcloned via EcoRI and XbaI digest
777 and PCR from pBDG598 using primers SLBP0045-7. Hemagglutinin epitope (HA) tags were
778 inserted via XbaI and SacII digest using ssDNA oligos AB42-HA (SLBP0088) or GagPrLD-HA
779 (SLBP0087) and HA-tag-SacII (SLBP0086).

780 pBDG1647 was kindly provided by K. Pachulska-Wieczorek and is the mini-Ty1*his3*-AI
781 plasmid (pJC994) which was constructed by deleting the HpaI-SnaBI fragment of pGTy1*his3AI*-
782 [Δ 1] (nucleotides 818-5463 of Ty1-H3) (6).

783 pBDG1781 contains pGTy1nt.241-5561 which is pEIB (“enzyme-in-a-box”). pEIB was
784 kindly provided by J. Strathern. It was created by deleting the BglIII-NcoI fragment which
785 removes the U3 polypurine tract (PPT) and 3' LTR, preventing reverse transcription of the Ty1
786 RNA produced from pEIB. The original pEIB provided by J. Strathern also contained a multiply
787 mutated primer binding sequence (PBS), disrupting complementarity to the initiator tRNA_i^{Met}
788 which primes reverse transcription. pBDG1781 was corrected back to the original Ty1H3 PBS
789 sequence via XhoI and HpaI digest and PCR from pBDG598 using primers SLBP0116-7.

790 pBDG1781 derivatives were generated by replacing the Gag_{PrLD} with custom commercial
791 gene fragments (Integrated DNA Technologies (IDT) and Twist Bioscience) via XhoI and HpaI
792 digest. *PrLD* Δ was cloned using SLBG0030 and the chimeras were cloned using overlapping
793 gene fragments SLBG0024, SLBG0025 and a gene fragment encoding the foreign prion
794 domain. The A β ₁₋₄₂ sequence used is identical to that in pBDG1691 provided by Y. Chernoff and
795 contains a silent mutation at codon 3 (GAA>GAG) to remove an EcoRI site. Mouse PrP (UniProt
796 P04925) amino acid sequence was codon optimized for *S. cerevisiae* using the IDT codon
797 optimization tool.

798 pBDG1799 contains mature Gag (amino acids 1-401) driven by the *GAL1* promoter
799 fused to GFP-(S65T) with a 7 amino acid linker (nt. CGGATCCCCGGGTTAATTAAC) followed
800 by the *ADH1* terminator sequence, which was kindly provided by J. Curcio on plasmid BJC1066,

801 which is in a pRS415 backbone. The expression construct was subcloned to pRS413 (97) using
802 primers SLBP0221-2 and inserted via XhoI and SacII digest to create pBDG1799. Derivatives
803 were subcloned via XhoI and BbvCI digest and PCR from the corresponding chimeric pEIB
804 plasmids using primers SLBP0117 and SLBP0194.

805 pBDG598 is pGTy1mhis3-AI, described in (59), and is driven by the *GAL1* promoter and
806 is marked with the *his3-AI* retrotranscript indicator gene. Derivatives were subcloned via XhoI
807 and HpaI digest and PCR from the corresponding chimeric pEIB plasmids using primers
808 SLBP0116-7. All plasmids generated were verified by DNA sequencing.

809

810 **SDD-AGE.** Semi-denaturing detergent-agarose gel electrophoresis (SDD-AGE) was adapted
811 from published methods (53, 54). Yeast were subcultured from an overnight SC-Ura starter
812 culture into SC-Ura \pm 100 μ M CuSO₄ and grown overnight at 30 °C. Approximately 1×10^8 cells
813 were lysed in 200 μ L of ice cold Buffer A (50 mM HEPES, pH 7.5; 150 mM NaCl; 2.5 mM EDTA;
814 1% Triton X-100) with 400 μ g/mL PMSF, 16 μ g/mL each of aprotinin, leupeptin, pepstatin, and 6
815 mM DTT by vortexing with glass beads twice for 5 minutes at 4 °C. Cell debris was removed by
816 centrifugation for 2 minutes at 5000 rpm at 4 °C. 4X sample buffer (2X TAE; 20% glycerol; 4%
817 SDS; bromophenol blue) was added to the supernatant and run on a 13 cm 1.8% agarose gel
818 containing 1X TAE and 0.1% SDS at 50 V for several hours until the dye front reached 1 cm
819 from the bottom of the gel. Proteins were transferred to PVDF using 1X TBS by downward
820 capillary transfer overnight at room temperature. The membrane was immunoblotted by
821 standard immunoblotting.

822

823 **Ty1*his3-AI* mobility assays.** Ty1 retromobility events were detected using the *his3-AI*
824 retromobility indicator gene (59) by qualitative and quantitative assays (58). Qualitative assays
825 were printed from glucose plates onto galactose plates, grown for 48 h at 22 °C, then printed to
826 glucose plates lacking histidine and grown at 30 °C. Quantitative retromobility frequencies were
827 determined from galactose inductions diluted in water, plated on synthetic dropout media, and
828 colonies counted. All experiments were galactose-induced for 48 h at 22 °C. Data represent at
829 least 8 independent galactose inductions; *p*-values were calculated by two-sided Student's *t*-
830 test. Determination of likely cDNA recombinants versus likely genomic insertions was conducted
831 on His⁺ papillae isolated after 48 hr galactose induction. The *URA3*-bearing plasmid was
832 counter-selected by growth on media containing 5-fluoroorotic acid. Cells that had lost the
833 *TRP1*-bearing plasmid after single colony passaging on YPD were determined by printing to
834 SC-Trp plates. Ura⁻/Trp⁻ cells were tested for growth on SC-His. Loss of the His⁺ phenotype

835 concomitant with plasmid loss indicates a likely cDNA recombinant since the only Ty1 sequence
836 present for homologous recombination is on the plasmids. Retention of the His⁺ phenotype
837 indicates a likely genomic insertion. *p*-values were calculated by Fisher's exact test compared to
838 wildtype. 100 retromobility events was selected for feasibility of data collection after estimating
839 required sample size of 126 by *a priori* power analysis to detect increased recombination
840 frequency of a 10% effect size with 80% power compared with a 5% recombinant frequency in
841 wildtype piloted with 20 retromobility events. Power analysis for Fisher's exact test was
842 performed using G*Power 3.1 (98).

843

844 **Immunoblotting.** Total yeast protein was prepared by trichloroacetic acid (TCA) precipitation
845 using standard techniques (58, 96). Briefly, cells were broken by vortexing in the presence of
846 glass beads in 20% TCA and washed in 5% TCA. Proteins were separated on 8% or 10% SDS-
847 PAGE gels. PVDF membranes were immunoblotted with antibodies at the following dilutions in
848 2.5% milk-TBST: mouse monoclonal anti-HA antibody clone 2-2.2.14 (Invitrogen cat. no. 26183)
849 (1:1000), mouse monoclonal anti-TY tag antibody clone BB2 (kindly provided by S. Hajduk)
850 (1:10,000) (99), mouse monoclonal anti-IN clone 8B11 (kindly provided by J. Boeke) (1:1,000),
851 rabbit polyclonal anti-RT (Boster Bio cat. no. DZ33991) (1:500), or mouse monoclonal anti-Pgk1
852 antibody clone 22C5D8 (Invitrogen cat. no. 459250) (1:1000). Immune complexes were
853 detected with WesternBright enhanced chemiluminescence (ECL) detection reagent (Advansta
854 cat. no. K-12049-D50). All imaging was done using a ChemiDoc MP (Bio-Rad). Precision Plus
855 Kaleidoscope protein standards (Bio-Rad cat. no. 1610395) were used to estimate molecular
856 weights.

857

858 **Live cell fluorescence microscopy.** Following 24 or 48 hr galactose induction, cells were
859 imaged directly in growth media on positively charged slides (Globe Scientific cat. no. 1358W)
860 using a Zeiss Axio Observer.Z1 epifluorescence microscope equipped with an AxioCam HSm
861 camera and captured using AxioVision v4.8.2 software (Carl Zeiss Microscopy).

862

863 **Sucrose gradient sedimentation.** Following 48 hr galactose induction, a 100 mL culture was
864 harvested, and cells were broken in 15 mM KCl, 10 mM HEPES- KOH, pH 7, 5 mM EDTA
865 containing RNase inhibitor (100 U/mL), and protease inhibitors (16 µg/mL aprotinin, leupeptin,
866 pepstatin A and 2 mM PMSF) in the presence of glass beads. Cell debris was removed by
867 centrifuging the broken cells at 10,000 x g for 10 min at 4°C. Clarified whole cell extract in 500
868 µL of buffer was applied to a 7-47% continuous sucrose gradient and centrifuged using an

869 SW41 Ti rotor at 25,000 rpm (77,000 x g) for 3 hr at 4°C. After centrifugation, 9 x 1.2 mL
870 fractions were collected, and input and fractions were immunoblotted with TY-tag antibody to
871 detect Gag. Densitometric analysis was performed using Image Lab (Bio-Rad, v. 6.0.1).

872

873 **Transmission electron microscopy preparation and imaging of yeast cells.** Following 48 hr
874 galactose induction, or 24 hr induction for GFP-expressing strains, cells were fixed with 4%
875 formaldehyde - 2.5% glutaraldehyde in 0.1 M sodium cacodylate pH 7.4 for 2 hr at 4 °C, washed
876 three times with cold PBS, once with cold 0.1 M KPO₄ (pH 6.5), and once with cold P solution
877 (1.2 M sorbitol, 0.1 M KPO₄ pH 6.5). Cells were spheroplasted in P solution with 25 mM DTT for
878 15 min at 37 °C using 400 µg/mL of Zymolyase-20T. Spheroplasts were gently washed three
879 times with cold PBS, stored in 0.1 M sodium cacodylate pH 7.4 at 4 °C, and transported to the
880 Robert P. Apkarian Integrated Electron Microscopy Core. Then the cells were washed in fresh
881 0.1 M cacodylate buffer and spun for 5 minutes at 8000 rpm on an Eppendorf Centrifuge 5430.
882 The cells were spun between each step and were processed in the microcentrifuge tubes in
883 which they were received. After two 0.1 M cacodylate buffer washes of ten minutes each, the
884 cells were post-fixed for an hour in 1% buffered osmium tetroxide. Following two ten-minute
885 washes in distilled water, the cells were en-bloc stained with 0.5% Uranyl Acetate in 0.1 M
886 sodium acetate for 30 minutes. The cells were washed in distilled water for 10 minutes, and
887 then dehydrated in an ascending ethanol series of 15-minute steps starting with 25% and
888 ending with 100% ethanol followed by two 15-minute steps of propylene oxide (PPO). The cells
889 were infiltrated with Eponate12 (Ted Pella, Inc.) epoxy resin in four steps: 1:2 of resin to PPO,
890 1:1 resin to PPO, 2:1 resin to PPO, and two changes of 100% resin. All resin steps were for 4
891 hours to overnight, followed by a final change of fresh 100% resin. The cells in resin were then
892 polymerized for two to three days at 60 °C. After release from the tubes, the sample blocks were
893 faced. Ultrathin sections of 70 to 80 nm were made using a Reichert Ultracut S and a Diatome
894 diamond knife. The sections were collected onto 200 mesh copper grids with Carbon stabilized
895 Formvar™ support film then post-stained with 5% Uranyl Acetate and Reynold's Lead Citrate.
896 Images were acquired using an Ultrascan 1000, 2K x 2K CCD digital camera, on a JEOL
897 JEM1400 TEM operated at 80kV. Micrographs of 140-500 cells per strain were analyzed and
898 representative images were selected for publication. Particle diameters were measured single-
899 blind using FIJI version 2.3.0 (100) by counting at least 60 particles from all cells visible in the
900 field of view (1-3 cells) in at least two separate micrographs.

901

FIG. S1




Fig S1. PrLD predictions for Ty1. Schematic of the Ty1 Gag-Pol p199 polyprotein (*top*). Below are bioinformatic analyses aligned with the schematic above: yeast prion-like amino acid composition (PLAAC), predicted amyloidogenic regions (ArchCandy), predicted protein disorder (PrDOS), predicted disordered (green) and globular (grey) regions (GlobPlot2.3).

FIG. S2




Fig S2. Prionogenic domains are intrinsically disordered in experimental and predicted protein structures. Schematics of protein domains (*top*) and experimentally determined protein structures with the methodology are noted (*bottom*). Amino acid coordinates are shown above cartoon representations of structures predicted by AlphaFold (orange) aligned to published structures (blue). Prion domains are colored in dark green, and their predicted disordered loops are shown in stick representation to aid visualization. PDB accession numbers and reported resolutions for published structures, and RMSD over the common residues between the published and predicted structures, are indicated.

FIG. S3




Fig S3. Gag_{PrLD} nucleates a Sup35-based prion reporter. (A and B) Qualitative prionogenesis of Sup35 fusions; growth on SC-Ade indicates either a suppressor mutation or [PSI⁺] prionogenesis. Expression of Sup35 fusions were induced with 150 μ M CuSO₄. A representative image of at least 3 experiments is shown. (C) SDD-AGE analysis of Sup35NM-HA with and without Gag_{PrLD} fusion. Expression of Sup35 fusions were induced with 100 μ M CuSO₄. Monomers and high-molecular weight aggregates of chimeric proteins were detected with anti-HA antibody. A representative image of at least 3 experiments is shown. (D) Curing of Ade⁺ colonies by guanidine hydrochloride (GdHCl) of Sup35NM chimeras. One [psi⁻] Sup35NM-A β fusion control strain is shown induced to [PSI⁺] and cured. Three independent inductions of a [psi⁻] Sup35NM-GagPrLD fusion are shown induced to [PSI⁺] and cured. [PSI⁺] yeast cells are white on YPD and grow on SC-Ade while [psi⁻] and cured cells are red on YPD and do not grow on SC-Ade.

FIG. S4





Fig S4. Gag chimeras likely disrupt Ty1 RNA functions and modestly increase cDNA recombination with plasmid-borne mini-Ty1*his3-AI*. (A) Qualitative retromobility of chimeric Gag constructs in a single pGTy1*his3-AI* plasmid. Growth on media lacking histidine indicates a retromobility event. A representative image of at least 3 replicates is shown. (B) Protein extracts prepared from galactose-induced yeast cells expressing the indicated Gag constructs in a single plasmid were immunoblotted for Gag. Pgk1 serves as a loading control. Migration of molecular weight standards is shown alongside the immunoblots. A representative image of at least 3 replicates is shown. (C) Schematic of two major retromobility pathways that lead to His⁺ cells detected in retromobility assays using Ty-less strains. cDNA recombination and genomic insertion can be differentiated by allowing for plasmid loss after a retromobility event and testing for the retention of growth on medium lacking histidine. (D) Table indicating the ratio of cDNA recombinants versus genomic insertions, *p*-values are compared to wildtype.

FIG. S5

A.



B.




Fig S5. Chimeric Gag-GFP after 48 hr galactose induction. (A) Live-cell yeast fluorescence microscopy of strains expressing chimeric Gag-GFP after 48 hr galactose induction. Normaski (DIC) and GFP channels are shown with cell outlines added to GFP channels based on DIC images. The strain labels are colored to match the most common foci observed. White arrows indicate cells with a single large focus. Scale bars represent 5 μm. (B) Quantitation of categories of foci observed as a percentage. The multiple foci category includes cells with multiple large foci, one or more small foci, or a combination of both sizes. Exact cell counts are provided in Supplementary Table 2.

FIG. S6




Fig S6. Thin-section TEM of Gag-GFP strains. Thin-section TEM of 24 hr galactose-induced cells expressing Gag-GFP chimeras. Representative cells are shown. Scale bars represent 500 nm.

FIG. S7




Fig S7. VLP diameter of Gag-PrLD chimeras. Diameter measurements of particles in galactose-induced cells expressing Gag chimeras visualized by thin-section TEM. Each bar represents the mean diameter, displayed as points, and the error bar \pm the standard deviation. The median diameter is noted above each bar, the number of particles measured is noted at the base of each bar. Particles from all strains are significantly smaller as calculated from a two-sided Student's *t*-test compared with WT.

909 Supplementary Table S1. Retromobility frequencies.

Strain	Label	Retromobility Frequency	Std Dev	p -value ^a	Biological replicates
DG4457	WT	6.46×10^{-5}	2.72×10^{-5}	Reference	20
DG4197	<i>PrLDΔ</i>	8.75×10^{-9}	2.47×10^{-8}	4.75×10^{-7}	8
DG4198	Sup35N	6.57×10^{-5}	3.59×10^{-5}	0.933	8
DG4201	Ure2	0	0	4.74×10^{-7}	8
DG4242	PrP	1.22×10^{-6}	5.59×10^{-7}	6.51×10^{-7}	8
DG4241	A β	0	0	4.74×10^{-7}	8

910 ^a Calculated by two-sided Student's *t*-test

911 Supplementary Table S2. Gag-GFP chimera fluorescent microscopy cell counts.

Strain	Label	GFP negative	Diffuse	Multiple foci ^a	Single large focus	Total cells
<i>24 hr induction</i>						
DG4513	WT	32	0	307	2	341
DG4514	<i>PrLDΔ</i>	48	293	50	0	391
DG4515	Sup35N	24	4	276	5	309
DG4516	Ure2	38	320	7	0	365
DG4517	PrP	44	45	196	48	333
DG4518	Aβ	65	23	127	89	304
<i>48 hr induction</i>						
DG4513	WT	108	0	135	1	244
DG4514	<i>PrLDΔ</i>	83	159	58	1	301

912 ^a This category includes multiple large foci, one or more small foci, or a combination of both sizes.

913 Supplementary Table S3. Yeast strains used in this study.

Strain	Genotype	Plasmids	Source
GT409	<i>Saccharomyces cerevisiae</i> MAT α <i>ade1-14 his3 leu2-3,112 lys2 trp1 ura3-52 [psi⁻ pin⁻]</i>		(53)
SLBY294	GT409	SLBB027	This study
SLBY286	GT409	SLBB021	This study
SLBY295	GT409	SLBB028	This study
SLBY287	GT409	SLBB022	This study
SLBY285	GT409	SLBB020	This study
DG4218	GT409	BDG1691	This study
DG4219	GT409	BDG1701	This study
DG3582	<i>Saccharomyces paradoxus</i> MAT α <i>gal3 his3-Δ200hisG trp1-1* ura3 Ty-less</i>		(58)
DG4457	DG3582	BDG1647, BDG1781	This study
DG4197	DG3582	BDG1647, BDG1680	This study
DG4198	DG3582	BDG1647, BDG1681	This study
DG4201	DG3582	BDG1647, BDG1684	This study
DG4241	DG3582	BDG1647, BDG1712	This study
DG4242	DG3582	BDG1647, BDG1713	This study
DG4441	DG3582	BDG673, BDG674	This study
DG4156	DG3582	BDG598	This study
DG4447	DG3582	SLBB050	This study
DG4448	DG3582	SLBB051	This study
DG4449	DG3582	SLBB052	This study
DG4513	DG3582	BDG1799	This study
DG4514	DG3582	BDG1800	This study
DG4515	DG3582	BDG1801	This study
DG4516	DG3582	BDG1802	This study
DG4517	DG3582	BDG1803	This study
DG4518	DG3582	BDG1804	This study

914

915 Supplementary Table S4. Plasmids used in this study.

Plasmid	Description	Markers	Source
pBDG598	pGTy1 <i>his3-AI</i>	<i>URA3/2μ</i>	(59)
pSLBB050	pBDG598- <i>PrLD</i> Δ	<i>URA3/2μ</i>	This study
pSLBB051	pBDG598-Sup35N ₂₋₁₂₃	<i>URA3/2μ</i>	This study
pSLBB052	pBDG598-PrP ₉₀₋₁₅₉	<i>URA3/2μ</i>	This study
pBDG1647	pGTy1 <i>hisAI</i> - Δ nt818-5463	<i>URA3/2μ</i>	(6)
pBDG1781	pGTy1nt.241-5561	<i>TRP1/2μ</i>	This study
pBDG1680	pBDG1781- <i>PrLD</i> Δ	<i>TRP1/2μ</i>	This study
pBDG1681	pBDG1781-Sup35N ₂₋₁₂₃	<i>TRP1/2μ</i>	This study
pBDG1684	pBDG1781-Ure2 ₁₇₋₇₆	<i>TRP1/2μ</i>	This study
pBDG1712	pBDG1781-A β ₁₋₄₂	<i>TRP1/2μ</i>	This study
pBDG1713	pBDG1781-PrP ₉₀₋₁₅₉	<i>TRP1/2μ</i>	This study
pBDG673	pRS424	<i>TRP1/2μ</i>	(97)
pBDG674	pRS426	<i>URA3/2μ</i>	(97)
pBDG1691	pCUP1-SUP35NM-A β ₁₋₄₂	<i>URA3/CEN</i>	(53)
pBDG1701	pCUP1-SUP35NM-Gag _{PrLD}	<i>URA3/CEN</i>	This study
pSLBB020	pCUP1-SUP35NM-A β ₁₋₄₂ -HA	<i>URA3/CEN</i>	This study
pSLBB021	pCUP1-SUP35NM-Gag _{PrLD} -HA	<i>URA3/CEN</i>	This study
pSLBB022	pCUP1-SUP35N-Gag _{PrLD} -HA	<i>URA3/CEN</i>	This study
pSLBB027	pCUP1-SUP35NM-HA	<i>URA3/CEN</i>	^a
pSLBB028	pCUP1-SUP35N-HA	<i>URA3/CEN</i>	(53)
pBDG1799	pGAL-Gag ₁₋₄₀₁ -GFP	<i>HIS3/CEN</i>	This study
pBDG1800	pBDG1799- <i>PrLD</i> Δ	<i>HIS3/CEN</i>	This study
pBDG1801	pBDG1799-Sup35N ₂₋₁₂₃	<i>HIS3/CEN</i>	This study
pBDG1802	pBDG1799-Ure2 ₁₇₋₇₆	<i>HIS3/CEN</i>	This study
pBDG1803	pBDG1799-A β ₁₋₄₂	<i>HIS3/CEN</i>	This study
pBDG1804	pBDG1799-PrP ₉₀₋₁₅₉	<i>HIS3/CEN</i>	This study

916 ^a Kindly provided by Y. Chernoff.

917 Supplementary Table S5. Primers used in this study.

Construct	Description	Oligos (5' - 3')
SLBP0045	SupM-PrLDF	GAAGTGGATGACGAAGTTGAATTCAACCCCATCATGCCTCTCC
SLBP0046	SupN-PrLDF	CAACCACAGTCTCAAGGTGAATTCAACCCCATCATGCCTCTCC
SLBP0047	Sup-PrLDR	CACCGGGTGGCGCGCTCTAGATTATGATGATGGATACTGCGG
SLBP0086	HAtag-SacII	TACCCATACGACGTACCAGATTACGCTTGACCGGGTGGAGCTCCAA
SLBP0087	GagPrLD-HA	CAGTATCCATCATCATACCCATACGACGTA
SLBP0088	AB42-HA	GGTGTTCATAGCGTACCCATACGACGTA
SLBP0194	Ty1 779 Rev	CATATCAGAGTCCGCTGAGG
SLBP0116	Ty1 835 Rev	GGAAAGTCATTAGGTGAGG
SLBP0117	GTy1 Xho Fwd	GTATTACTTCTTATTCTCGAGG
SLBP0221	pRS Fwd	TTGGGTACCGGGCCC
SLBP0222	pRS Rev	AAAGCTGGAGCTCCACC

918

919 Supplementary Table S6. Gene fragments used in this study.

Construct	Description	Oligos (5' - 3')
SLBG0024	Ty1 XhoI PrLD	ACTTCTTATTCCTCTACCGCCTCGAGGAGAACTTCTAGTATATTCTGTATACCT AATATTATAGCCTTTATCAACAATGGAATCCCAACAATTATCTCAACATTCACC CAATTCTCATGGTAGCGCCTGTGCTTCGGTTACTTCTAAGGAAGTCCACACAAA TCAAGATCCGTTAGACGTTTCAGCTTCCAAAACAGAAGAATGTGAGAAGGCTTC CACTAAGGCTAACTCTCAACAGACAACAACACCTGCTTCATCAGCTGTTCCAGA G
SLBG0025	Ty1 702-840	GTTGGAACGCCTCTGAGCACTCCATCACCTGAGTCAGGTAATACATTTACTGAT TCATCCTCAGCGGACTCTGATATGACATCCACTAAAAAATATGTCAGACCACCA CCAATGTAACTCACCTAATGACTTTCCAA
SLBG0026	Ty1 Sup35N	ACAACACCTGCTTCATCAGCTGTTCCAGAGTCGGATTCAAACCAAGGCAACAAT CAGCAAAACTACCAGCAATACAGCCAGAACGGTAACCAACAACAAGGTAACAAC AGATACCAAGGTTATCAAGCTTACAATGCTCAAGCCCAACCTGCAGGTGGGTAC TACCAAAATTACCAAGGTTATTCTGGGTACCAACAAGGTGGCTATCAACAGTAC AATCCCAGCGCGGTTACCAGCAACAGTATAATCCTCAAGGAGGCTATCAACAG TACAATCCTCAAGGCGGTTATCAGCAGCAATTCAATCCACAAGGTGGCCGTGGA AATTACAAAACCTTCAACTACAATAACAATTTGCAAGGATATCAAGCTGGTTTC CAACCACAGTCTCAAGGTGTTGGAACGCCTCTGAGCACTCCATCACCT
SLBG0029	Ty1 Ure2	ACAACACCTGCTTCATCAGCTGTTCCAGAGCGTCAAGTAAACATAGGAAACAGG AACAGTAATACAACCACCGATCAAAGTAATATAAATTTTGAATTTTCAACAGGT GTAAATAATAATAATAATAACAATAGCAGTAGTAATAACAATAATGTTCAAAAC AATAACAGCGGCCGAATGGTAGCCAAAATAATGATAACGAGAATAATGTTGGA ACGCCTCTGAGCACTCCATCACCT
SLBG0030	Ty1 PrLD Δ	ACTTCTTATTCCTCTACCGCCTCGAGGAGAACTTCTAGTATATTCTGTATACCT AATATTATAGCCTTTATCAACAATGGAATCCCAACAATTATCTCAACATTCACC CAATTCTCATGGTAGCGCCTGTGCTTCGGTTACTTCTAAGGAAGTCCACACAAA TCAAGATCCGTTAGACGTTTCAGCTTCCAAAACAGAAGAATGTGAGAAGGCTTC CACTAAGGCTAACTCTCAACAGACAACAACACCTGCTTCATCAGCTGTTCCAGA GGTTGGAACGCCTCTGAGCACTCCATCACCTGAGTCAGGTAATACATTTACTGA TTCATCCTCAGCGGACTCTGATATGACATCCACTAAAAAATATGTCAGACCACC ACCAATGTAACTCACCTAATGACTTTCCAA

SLBG0035 Ty1 Abeta CTTTCATCAGCTGTTCCAGAGGATGCAGAGTTCGACATGACTCAGGATATGAAG
TTCATCATCAAAAATTGGTGTCTTTGCAGAAGATGTGGGTTCAAACAAAGGTG
CAATCATTGGACTCATGGTGGGCGGTGTTGTCATAGCGGTTGGAACGCCTCTGA
GCAC

SLBG0036 Ty1 PrP CTTTCATCAGCTGTTCCAGAGCAGGGAGGAGGTACACACAATCAGTGAATAAAC
CAAGCAAACCGAAGACGAACTTGAAACACGTCGCCGGCGCCGGCTGCAGGGG
CGGTTGTTGGAGGACTTGGTGGGTATATGCTGGGCAGTGCTATGAGCCGTCCCA
TGATCCATTTTGGTAACGATTGGGAAGACCGTTATTATAGGGAGAACATGTATA
GGTACCCTAATCAGGTTGGAACGCCTCTGAGCAC

920